Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bicycle Therapeutics (BCYC) Change in Account Payables (2018 - 2025)

Bicycle Therapeutics (BCYC) has disclosed Change in Account Payables for 8 consecutive years, with -$5.1 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Change in Account Payables fell 309.2% year-over-year to -$5.1 million, compared with a TTM value of $6.7 million through Sep 2025, up 295.5%, and an annual FY2024 reading of $3.1 million, down 61.32% over the prior year.
  • Change in Account Payables was -$5.1 million for Q3 2025 at Bicycle Therapeutics, down from $6.1 million in the prior quarter.
  • Across five years, Change in Account Payables topped out at $10.7 million in Q4 2024 and bottomed at -$5.9 million in Q1 2024.
  • Average Change in Account Payables over 5 years is $571789.5, with a median of -$255000.0 recorded in 2022.
  • The sharpest move saw Change in Account Payables crashed 684.71% in 2023, then skyrocketed 1515.08% in 2025.
  • Year by year, Change in Account Payables stood at $926000.0 in 2021, then plummeted by 355.94% to -$2.4 million in 2022, then soared by 275.82% to $4.2 million in 2023, then skyrocketed by 156.49% to $10.7 million in 2024, then plummeted by 147.44% to -$5.1 million in 2025.
  • Business Quant data shows Change in Account Payables for BCYC at -$5.1 million in Q3 2025, $6.1 million in Q2 2025, and -$5.0 million in Q1 2025.